InMed Pharmaceuticals (INM) Operating Leases: 2021-2025
Historic Operating Leases for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $215,478.
- InMed Pharmaceuticals' Operating Leases fell 79.63% to $215,478 in Q3 2025 from the same period last year, while for Sep 2025 it was $215,478, marking a year-over-year decrease of 79.63%. This contributed to the annual value of $305,755 for FY2025, which is 52.59% down from last year.
- According to the latest figures from Q3 2025, InMed Pharmaceuticals' Operating Leases is $215,478, which was down 29.53% from $305,755 recorded in Q2 2025.
- Over the past 5 years, InMed Pharmaceuticals' Operating Leases peaked at $1.2 million during Q4 2023, and registered a low of $15,994 during Q2 2023.
- Over the past 3 years, InMed Pharmaceuticals' median Operating Leases value was $419,347 (recorded in 2025), while the average stood at $495,157.
- Its Operating Leases has fluctuated over the past 5 years, first plummeted by 95.89% in 2023, then spiked by 3,931.92% in 2024.
- Over the past 5 years, InMed Pharmaceuticals' Operating Leases (Quarterly) stood at $825,427 in 2021, then slumped by 77.72% to $183,902 in 2022, then surged by 534.56% to $1.2 million in 2023, then crashed by 54.65% to $529,248 in 2024, then slumped by 79.63% to $215,478 in 2025.
- Its Operating Leases stands at $215,478 for Q3 2025, versus $305,755 for Q2 2025 and $419,347 for Q1 2025.